8-KEarnings & ResultsExhibits & Filings

AbbVie Inc. 8-K Report, Financial Results (Oct 28, 2016)

Filed October 28, 2016For Securities:ABBV

Summary

AbbVie Inc. (ABBV) filed an 8-K report on October 28, 2016, to announce its financial results for the third quarter ended September 30, 2016. This filing primarily serves to furnish the press release detailing these results, making it a crucial source of up-to-date performance information for investors. The report itself does not contain new operational details beyond what is presented in the accompanying press release. Investors interested in AbbVie's performance during the third quarter of 2016 should refer to the furnished press release (Exhibit 99.1) for comprehensive financial data, including revenue, earnings per share, and potentially forward-looking guidance. This 8-K acts as the official SEC notification of these results, highlighting the company's financial condition and operational outcomes for the period.

Key Highlights

  • 1AbbVie Inc. filed an 8-K on October 28, 2016, to report its Q3 2016 financial results.
  • 2The report's primary purpose is to furnish the press release announcing these financial results (Exhibit 99.1).
  • 3The filing falls under Item 2.02 (Results of Operations and Financial Condition).
  • 4The event date for the earliest reported event is October 27, 2016.
  • 5The press release contains key financial performance indicators for the quarter ended September 30, 2016.
  • 6William J. Chase, AbbVie's Executive Vice President and Chief Financial Officer, signed the report.
  • 7This 8-K serves as the official SEC dissemination of AbbVie's Q3 2016 financial performance.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially report AbbVie Inc.'s financial results for the third quarter ended September 30, 2016, by furnishing the accompanying press release.

The detailed financial results for the third quarter ended September 30, 2016, are provided in the press release dated October 28, 2016, which is included as Exhibit 99.1 to this 8-K filing.

No, this 8-K report primarily focuses on reporting financial results and does not contain new operational strategies or significant business updates beyond what is detailed in the Q3 2016 earnings press release.

William J. Chase, AbbVie's Executive Vice President and Chief Financial Officer, is the key executive who signed this 8-K report, attesting to the accuracy of the reported financial information.